Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2005-08-02
2008-07-08
Weber, Jon P (Department: 1657)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
active
07396524
ABSTRACT:
Methods for screening compounds for their potential to induce or inhibit a cardiac arrhythmia are disclosed. The methods comprise determining the ratio of the time constant (τ) of ICa,Lrecovery in tissue expressing the L-type calcium channel or any subunit or combination thereof of the L-type calcium channel treated with a test compound to the ventricular repolarization time of cardiac tissue treated with a test compound. The methods further comprise determining an arrhythmic risk score for a specified dose of a test compound.
REFERENCES:
patent: 6847840 (2005-01-01), DePasquale et al.
patent: 2003/0013136 (2003-01-01), Balser et al.
patent: 2003/0108924 (2003-06-01), George et al.
patent: 2003/0235838 (2003-12-01), Keating et al.
patent: 2004/0161805 (2004-08-01), Heylen et al.
patent: 2004/0170993 (2004-09-01), Fishman et al.
Takahara et al. AJH May 2003 vol. 16(5):part 2, (abstract).
Thomas et al. J of Cardiovascular Pharmacology 2003 41:140-147.
Owens et al. Pharmacotherapy 2002 22(5):663-672.
Antzelevitch, C. et al., “Cellular and ionic mechanisms underlying erythromycin-induced long QT and torsade de pointes,”J. Am. Coll. Cardiol.1996; 28(7):1836-1848.
Antzelevitch, C. et al.,J Cardiovasc Electrophysiol2003; 14:114-115.
Banyasz, T. et al., “Endocardial versus epicardial differences in L-type calcium current in canine ventricular myocytes studied by action potential voltage clamp,”Cardiovasc Res2003; 58: 66-75.
Bosse E., et al., “Stable and functional expression of the calcium channel α1 subunit from smooth muscle in somatic cell lines,”EMBO J.1992; 11:2033-2038.
Champeroux, P. et al., “Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres,”Br.J. Pharmacol.Feb. 2005;144:376-385.
Clancy& Rudy., “Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia,”Nature1999; 400: 566-569.
Coumel, P. et al., “Evaluation of drug-induced QT interval modifications in dynamic electrocardiography: the case of bepridil,”Fundam. Clin. Pharmacol.1993; 7: 61-68.
Coumel P. et al., “Safety of Bepridil: From Review of the European Data,”Am. J Cardiol1992; 69:75D-78D.
Doerr, T. et al., “Ionic currents contributing to the action potential in single ventricular myocytes of the guinea pig studied with action potential clamp,”Pflugers Arch1990; 416: 230-237.
Franz, M. R., “Current status of monophasic action potential recording: theories, measurements and interpretations,”Cardiovasc. Res.1999; 41:25-40.
Gerhardy, A. et al., “Generating and influencing Torsades de Pointes—like polymorphic ventricular tachycardia in isolated guinea pig hearts,”Basic Res. Cardiol.1998; 93: 285-294.
Gintant, G. A. et al., “The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis,”J Cardiovasc Pharmacol2001; 37:607-618.
Han, W. et al., “Ionic Remodeling of Cardiac Purkinje Cells by Congestive Heart Failure,”Circulation, 2001; 2095-2100.
Hondeghem, L. M., et al., “Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic,”Circulation, 2001;103:2004-13.
Joshi, A. et al., “Preclinical Strategies to Assess QT Liability and Torsadogenic Potential of New Drugs: The role of Experimental Models,”J Electrocardiol, 2004; 37 Suppl: 7-14.
Kang M-G. et al., “γ Subunit of Voltage-activated Calcium Channels,”J. Biol. Chem.2001; 279:32917-32924.
Krichhof, P. et al., “Amiodarone-Induced Postrepolarization Refractoriness Suppresses Induction of Ventricular Fibrillation,”J Pharmacol Exp Ther2003; 305: 257-263.
Kowey and Yan, “Proarrhythmias and Antiarrhythmias: Two Sides of the Same Coin,”Heart Rhythm, Sep. 2005, 2(9): 957-959.
Lacinova, L. et al., “The block of expressed L-type calcium channel is modulated by the β3subunit,”FEBS Lett.1995; 737:103-7.
Linz and Meyer, “Profile and kinetics of L-type calcium current during the cardiac ventricular action potential compared in guinea-pigs, rats and rabbits,”Pflugers Arch.2000; 439:588-599.
Lu, H. R. et al., “Species Plays an Important Role in Drug-Induced Prolongation of Action Potential Duration and Early Afterdepolarizations in Isolated Purkinje Fibers,”J Cardiovasc Electrophysicol, 2001; 12: 93-102.
Mattioni, T. A. et al., “Aminodarone in Patients with Previous Drug-Mediated Torsade de Pointes,”Ann. Intern. Med.1989;111:574-580.
Owens, R. C., Jr., “QT Prolongation with Antimicrobial Agents—Understanding the Significance,”Drugs, 2004; 64: 1091-1124.
Peng, S. et al., “Effects of Methylmercury on Human Neuronal L-Type Calcium Channels Transiently Expressed in Human Embryonic Kidney Cells (HEK-293),”J. Pharmacol. Exp. Ther.2002; 302:424-432.
Rampe, D. et al., “A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG,”FEBS Lett, 1997; 417:28-32.
Rials, S. J. et al., “Regression of Left Ventricular Hypertrophy With Captopril Restores Normal Ventricular Action Potential Duration, Dispersion of Refractoriness, and Vulnerability to Inducible Ventricular Fibrillation,”Circulation1997; 96:1330-1336.
Roden, D. M. “Drug-Induced Prolongation of the QT Interval,”N Engl. J. Med.2004; 350:1013.
Sanguinetti, M. C., et al., “A Mechanistic Link between an Inherited and an Acquired Cardiac Arrhythmia: HERG Encodes the IKrPotassium Channel,”Cell81:299-307 (1995).
Seisenberger, C., et al., “Two stable cell lines for screening of calcium channel blockers,”Naunyn Schmiedebergs Arch. Pharmacol.1995; 352:662-669.
Studenik, C. R. et al., “Differences in action potential and early afterdepolarization properties in LQT2 and LQT3 models of long QT syndrome,”Br J Pharmacol2001; 135:85-92.
Traebert, M. et al., “Inhibition of hERG K+currents by antimalarial drugs in stably transfected HEK293 cells,”Eur. J. Pharmacol.2004; 484:41-48.
van Opstal, J. M. et al., “Chronic Amiodarone Evokes No Torsade de Pointes Arrhythmias Despite QT Lengthening in an Animal Model of Acquired Long-QT Syndrome,”Circulation2001; 104:2722-2727.
Viswanathan & Rudy., “Pause induced afterdepolarizations in a long QT syndrome: a simulation study,”Cardiovasc Res.1999; 42: 530-542.
Welling, A., et al., “Stable Co-Expression of Calcium Channel α1, β and α2/δ Subunits in a Somatic Cell Line,”J. Physiol.1993; 471:749-765.
Yan, G-X. et al., “Characterisitcs and Distribution of M Cells in Arterially Perfused Canine Left Ventricular Wedge Preparations,”Circulation1998; 98: 1921-1927.
Yan, G-X. et al., “Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization,”Am. J. Physiol.2001 281: H1968-H1975.
Yan, G-X. et al., “Phase 2 Early Afterdepolarization as a Trigger of Polymorphic Ventricular Tachycardia in Acquired Long-QT Syndrome,”Circulation2001; 103:2851-2856.
Yan, G-X. et al., “Ventricular Repolarization Components on the Electrocardiogram,”J Am Coll Cardiol2003; 42: 401-409.
Yang, T. et al., “Drug Block of IKr: Model Systems and Relevance to Human Arrhythmias,”J. Cardiovasc. Pharmacol.2001; 38: 737-744.
Yang, T. et al., “Extracellular Potassium Modulation of Drug Block of IKr•Implications for Torsade de Pointes and Reverse Use-Dependence,”Circulation1996; 93: 407-411.
Yasuda T., et al., “Overexpressed Cavγ3 Inhibits N-type (Cav2.2) Calcium Channel Currents through a Hyperpolarizing Shift of “Ultra-slow” and “Closed-state” Inactivation,”J. Gen. Physiol.2004; 123:401-416
Main Line Health Heart Center
Ratner & Prestia
Shen Bin
Weber Jon P
LandOfFree
Methods for screening compounds for proarrhythmic risk and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for screening compounds for proarrhythmic risk and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for screening compounds for proarrhythmic risk and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3967086